MLTX SECURITIES LAWSUIT: MoonLake Immunotherapeutics Investors Are Notified to Contact BFA Law Before Tomorrow's December 15 Class Action Deadline

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from clinical trials that raised questions about the company's drug's regulatory approval and commercial viability [1][2][5]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, specifically through its investigational therapeutic sonelokimab (SLK) [3]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation from competitors [4]. Group 3: Clinical Trial Results - The VELA Phase 3 trials for sonelokimab reported disappointing results, with VELA-2 failing to meet its primary endpoint, which raised concerns about the drug's chances for regulatory approval [6]. - Following the announcement of the trial results on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].